Daraxonrasib NDA accepted for review in pancreatic cancer

What this means

Daraxonrasib is an experimental drug designed to block a specific mutated protein that drives the growth of certain cancers. The FDA has accepted Revolution Medicines' application to review the drug for patients with previously treated metastatic pancreatic cancer. A potential approval could offer a new treatment option for this difficult-to-treat disease.